LIFECORE BIOMEDICAL Reports 33.8% YOY Decline in Total Revenue for FY2023 Q4
September 13, 2023
🌥️Earnings Overview
On August 31 2023, LIFECORE BIOMEDICAL ($NASDAQ:LFCR) released their earnings for Q4 of FY2023, which ended on May 31 2023. Revenue for the quarter amounted to USD 31.6 million, a decrease of 33.8% from the same period of the prior year. Net income was reported to be -36.1 million, a slight improvement from -36.5 million in the same quarter of the prior year.
Analysis
GoodWhale is a great tool for analyzing the financials of companies like LIFECORE BIOMEDICAL. After running its analysis, GoodWhale gives LIFECORE BIOMEDICAL a medium risk rating, meaning that it is an average risk investment. This rating takes into consideration a variety of factors, such as the company’s income sheet, balance sheet, and financial journal. In fact, GoodWhale has identified three separate risk warnings in these documents. To take a closer look at these risks and more, simply register on goodwhale.com. This will give you access to all of the data and information that GoodWhale has provided and evaluated about LIFECORE BIOMEDICAL. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Lifecore Biomedical. More…
| Total Revenues | Net Income | Net Margin |
| 103.27 | -102.19 | -51.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Lifecore Biomedical. More…
| Operations | Investing | Financing |
| -34.46 | -4.15 | 56.06 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Lifecore Biomedical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 255.15 | 256.99 | -0.06 |
Key Ratios Snapshot
Some of the financial key ratios for Lifecore Biomedical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -44.1% | -26.5% | -48.9% |
| FCF Margin | ROE | ROA |
| -53.5% | -195.1% | -12.4% |
Peers
They are at the forefront of innovation, but they are not the only player in the game. Other companies such as Windlas Biotech Ltd, Biotika AS, and Daito Pharmaceutical Co Ltd offer similar services and products focused on the same goals of creating better medical treatments and products. Although these companies offer different solutions, they all strive for the same ultimate goal of improving the lives of people around the world.
– Windlas Biotech Ltd ($BSE:543329)
Windlas Biotech Ltd is a leading biopharmaceutical company based in India that specializes in research and development of innovative drugs for the treatment of various diseases and conditions. As of 2023, the company has a market cap of 4.69B, which is a testament to its success in providing high-quality healthcare products to customers around the world. Furthermore, its Return on Equity (ROE) stands at 8.66%, which demonstrates its efficient use of capital and strong profitability.
– Biotika AS ($LTS:0MZJ)
Daito Pharmaceutical Co Ltd is a leading Japanese pharmaceutical company based in Tokyo. Founded in 1959, Daito currently has a market cap of 35.64B as of 2023. The company’s Return on Equity (ROE), a measure of its profitability, has also been strong at 6.85%. Daito is known for its development of innovative and safe medications and products to improve the health and quality of life of its customers. The company has a wide range of products such as medical devices, diagnostics, and over-the-counter drugs that are sold both domestically and abroad.
Summary
LIFECORE BIOMEDICAL reported their financial results for FY2023 Q4 on August 31 2023, with total revenue of USD 31.6 million, down 33.8% year over year. Net income was reported to be at USD -36.1 million, compared to -36.5 million in the same period of the prior year. The stock price moved down shortly after the earnings were reported, indicating investor uncertainty about the company’s future prospects.
As an investor, it is important to consider the company’s profitability, cash flow, and growth prospects before investing in LIFECORE BIOMEDICAL stock. Analysts should further examine the company’s competitive landscape, management strategy, and review any additional risks when considering an investment in LIFECORE BIOMEDICAL.
Related Posts
Recent Posts
